UCB SA - BNP Paribas Fortis

These partnerships range from research collaborations to joint discovery, development and
commercialisation agreements and commercial partnerships with a wide range of small to large
companies, and include agreements with the following parties:
• Amgen Inc.: A partnership aimed at the research, development and commercialisation of
CDP7851, an antibody which works against sclerostin, a protein discovered by the UCB Group,
for the treatment of bone diseases and disorders such as osteoporosis and fracture healing.
• Astra Zeneca do Brasil Ltd : The UCB Group and Astra Zeneca do Brasil Ltd have entered into a
partnership relating to the registration and commercialization of Cimzia® in Brazil, which allows
Astra Zeneca do Brasil Ltd to be the exclusive distributor of Cimzia® in Brazil, with UCB
retaining the right to co-promotion of Cimzia® and any future line extensions.
• Bioseek, Inc. The UCB Group and BioSeek, Inc. have established a new compound evaluation
collaboration, under which BioSeek, Inc. will apply predictive human biology to evaluate the
therapeutic potential of novel molecules identified by UCB.
• deCODE chemistry Inc. & biostructures: UCB and deCODE are collaborating on the structurebased
discovery of novel small molecule anti-inflammatory products.
• Immunomedics Inc.: Immunomedics Inc. has granted to the UCB Group the exclusive worldwide
rights to develop, market and sell epratuzumab for all non-cancerous human diseases including
autoimmune disease indications.
• Inogent Laboratories Pvt. Ltd.: Inogent and UCB have agreed a multi-year collaboration to
support UCB’s early projects (up to proof of concept) on chemical process, analytical and
formulation development aspects.
• Jazz Pharmaceuticals: Jazz Pharmaceuticals has granted to the UCB Group the exclusive right to
commercialize Xyrem® in most European and certain other countries.
• King’s College London: UCB and Kings College London have agreed a multi-year collaboration
to support the university’s structure-based drug design activities.
• Lonza Limited: Lonza Limited and the UCB Group have a long-term supply agreement under
which Lonza Limited will manufacture PEGylated antibody fragment-based drugs for the UCB
Group.
• Millennium Pharmaceuticals, Inc.: The UCB Group and Millennium Pharmaceuticals, Inc. are
collaborating on the research, development and commercialization of new antibody therapeutics
aimed at one validated Millennium Pharmaceuticals, Inc. target.
• Neuroalliance-Biopharma Initiative: Schwarz Pharma, Universities of Bonn and Duisburg-Essen,
Landschaftsverband Rheinland, Forschungszentrum Jülich, Fraunhofer Institute, Protagen AG
and Life&Brain GmbH entered into a consortium agreement with the goal to set up diverse early
stage development agreements/collaborations among the partners in the neurology field
(medicines and diagnostics; the latter without involvement of the UCB Group). The initiative is
supported by the German government.
• Otsuka Pharmaceuticals: The UCB Group and Otsuka Pharmaceuticals have entered into
collaboration agreements pertaining to the development, licence and supply of Neupro® in Japan,
a development and commercialisation contract relating to Cimzia® and Keppra®in Japan, and a
development and commercialisation contract relating to Cimzia® in Korea.
• Proteros biostructures GmbH: A research agreement has been reached between UCB and
Proteros biostructures GmbH in relation to gene-to-structure based drug design for novel small
molecule anti-inflammatory drugs.
A11250830/2.25/23 Oct 2009 72